Louisiana State Employees Retirement System Acquires New Position in Perrigo Company plc $PRGO

Posted by Stanley Muller on Jul 7th, 2026

Louisiana State Employees Retirement System bought a new position in Perrigo Company plc (NYSE:PRGO – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 61,000 shares of the company’s stock, valued at approximately $655,000.

Several other institutional investors also recently made changes to their positions in PRGO. Fuller & Thaler Asset Management Inc. boosted its position in Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares during the period. Norges Bank acquired a new stake in Perrigo in the fourth quarter worth $42,607,000. Invesco Ltd. lifted its stake in Perrigo by 134.2% in the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after buying an additional 2,602,724 shares during the last quarter. ION Fund Management Ltd bought a new position in shares of Perrigo during the fourth quarter worth about $24,499,000. Finally, Vanguard Group Inc. grew its stake in shares of Perrigo by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. 95.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $19.33.

Read Our Latest Stock Analysis on PRGO

Perrigo Stock Up 2.3%

Shares of PRGO traded up $0.25 during mid-day trading on Tuesday, reaching $11.34. The company’s stock had a trading volume of 137,890 shares, compared to its average volume of 3,208,470. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -0.87, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The business has a fifty day moving average of $10.87 and a 200 day moving average of $12.10. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a 1 year low of $9.23 and a 1 year high of $28.43.

Perrigo (NYSE:PRGO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business earned $0.60 EPS. The business’s revenue for the quarter was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts forecast that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 10.2%. The ex-dividend date was Friday, May 29th. Perrigo’s payout ratio is currently -8.85%.

Perrigo Profile

(Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.